Karin Liwendahl - Immunovia Publ Chief Officer

All Insiders . Sweden . 
Stock . Immunovia publ AB . Stakeholders . Insider . Karin Liwendahl
IMMNOV Stock  SEK 0.33  0.01  2.94%   

Insider

Karin Liwendahl is Chief Officer of Immunovia publ AB
Age 61
Phone46 4 62 75 60 00
Webhttps://www.immunovia.com

Immunovia Publ Management Efficiency

The company has return on total asset (ROA) of (0.2617) % which means that it has lost $0.2617 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3789) %, meaning that it generated substantial loss on money invested by shareholders. Immunovia Publ's management efficiency ratios could be used to measure how well Immunovia Publ manages its routine affairs as well as how well it operates its assets and liabilities.
Immunovia publ AB has accumulated 27.16 M in total debt with debt to equity ratio (D/E) of 7.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Immunovia publ AB has a current ratio of 13.97, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Immunovia Publ until it has trouble settling it off, either with new capital or with free cash flow. So, Immunovia Publ's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immunovia publ AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immunovia to invest in growth at high rates of return. When we think about Immunovia Publ's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Katja MargellHansa Biopharma AB
N/A
Susanne LagerlundCantargia AB
N/A
MSc MScOncopeptides AB
53
MarcussCantargia AB
N/A
Anne LannerHansa Biopharma AB
54
Nina ValkamaCantargia AB
N/A
Peter MadsenCantargia AB
N/A
Thoas MDCantargia AB
61
Sren MScHansa Biopharma AB
58
Annika MBAOncopeptides AB
57
Rein BScCamurus AB
65
Dominique TersagoCantargia AB
61
Annette MattssonCamurus AB
57
Johanna ChristensenCantargia AB
N/A
MSc MDOncopeptides AB
N/A
Kjell SjstrmCantargia AB
N/A
Linda HolmstromOncopeptides AB
N/A
Pr MDOncopeptides AB
N/A
Adnan DeronicCantargia AB
N/A
Klaus SindahlHansa Biopharma AB
N/A
Jon AlonsoCamurus AB
50
Immunovia AB , a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. Immunovia AB was founded in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 46 people. Immunovia publ AB (IMMNOV) is traded on Stockholm Exchange in Sweden and employs 64 people.

Management Performance

Return On Equity-0.38
Return On Asset-0.26

Immunovia publ AB Leadership Team

Elected by the shareholders, the Immunovia Publ's board of directors comprises two types of representatives: Immunovia Publ inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunovia. The board's role is to monitor Immunovia Publ's management team and ensure that shareholders' interests are well served. Immunovia Publ's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunovia Publ's outside directors are responsible for providing unbiased perspectives on the board's policies.
Linda Mellby, Laboratory Director
Jeff Borcherding, Immunovia, US
Philipp Mathieu, CEO Pres
Karin Liwendahl, Chief Officer

Immunovia Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunovia Publ a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.38
Return On Asset-0.26
Operating Margin(201.30) %
Current Valuation536.89 M
Shares Outstanding22.63 M
Shares Owned By Insiders36.15 %
Shares Owned By Institutions4.60 %
Price To Earning(57.93) X
Price To Book2.21 X
Price To Sales683.47 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Other Information on Investing in Immunovia Stock

Immunovia Publ financial ratios help investors to determine whether Immunovia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immunovia with respect to the benefits of owning Immunovia Publ security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY